Pre-made Narsoplimab benchmark antibody ( Whole mAb, anti-MASP2 therapeutic antibody, Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Narsoplimab is the company’s lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement.
| Products Name (INN Index) | Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody |
|---|---|
| INN Name | Narsoplimab |
| Target | MASP2 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Omeros |
| Conditions Approved | NA |
| Conditions Active | Haemolytic uraemic syndrome,IgA nephropathy,Immediate hypersensitivity,Thrombotic microangiopathies,Glomerulonephritis,Lupus nephritis,Membranous glomerulonephritis |
| Conditions Discontinued | Stroke,Wet age-related macular degeneration |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MASP2 |
| Package |
